RCM-SS中文资料
缩写
电子液压辅助转向 自适应巡航控制 前部模块（ACC雷达模块） 仪表 电子控制单元 （集成中央组）触摸屏模块(14大切不是 触摸屏） （附件开关组）开关模块总成 空调 自动断路器（主继电器） 记忆座椅模块 通讯平台 （车载远程通讯模块（TGM)）
最终驱动控制模块（四驱模块） 电子限滑差速器模块（ELSD）（后排座椅 下） 传动系统模块（驾驶座椅下） 主动阻尼控制模块（ADCM（驾驶座椅下） 空气悬挂控制模块（ASCM）（驾驶座椅 下） 全轮驱动模块
制动差速锁 制动盘自干 电子防翻滚 下坡控制系统 拖车防摆动系统 坡道辅助起步 制动辅助系统 液压控制单元 乘员分类模块（座椅轨道位置+乘员重 量） 乘员约束控制器（安全气囊） 舒适座椅和方向盘模块 天窗 免提电话 雨量光线传感器 停车辅助系统 驾驶员车门模块 乘客侧车门模块 卫星无线电 车辆娱乐 功率放大器 电子车顶 左侧电动滑门 自动空调 左前车门模块 右前 左后 右后 入侵收发器模块
MODULE-STEERING COLUMN CONTROL MODULE-STEERING CONTROL MODULE - HEATED SEATS Sentry Key Immobilizer Module Sentry Key REmote Entry Module Wireless Control Module Wireless Ignition Node Radio Frequency Hub Module Keyless Ignition Node IGnition Node Module Remote Keyless Entry Tire Pressure Monitor Passive Entry Module and Keyless Go Vehicle Theft Alarm MODULE-INTRUSION
核电站规范RCC-M标准体系介绍
ASME未独立列出此卷
ASME包括在二、三级 设备内
第Ⅰ卷J篇 低压或 ASME包括在二、三级
常压贮罐
设备内
ASME与RCC-M的对应关系
ASME 第Ⅱ卷 材料 A篇-钢铁材料
RCC-M
说明
第Ⅱ卷 M篇 材料
RCC-M 第Ⅰ卷 A篇
• 第Ⅰ卷 A篇“总论”--汇集了应用RCC-M的
通用要求；
– 介绍了RCC-M文集结构、范围和应用； – 对不符合项的管理作出了规定； – 对采购、制造、焊接、检验等文件提出了要求，
设计规则：借鉴ASME第Ⅲ卷核动力装置设备 （NB、NC、ND、NG、NF）各篇的有关内容， 同时吸收了法国在工业发展实践中所取得 的成果。
制造与检验规则：法国本身核工业实践经验 的具体体现，以法国的制造和检验标准作 为基础。
RCC—M规范标准体系结构
第一卷
A篇 总论 Z 篇 技术性附录 B篇 1级设备 C篇 2级设备 D篇 3级设备 E篇 小型设备 G篇 反应堆堆内构件 H篇 支承件 J 篇 低压或常压储罐
的水压试验等。
RCC—M规范标准体系结构
▪ 第一卷的各篇在需要之处明确引用第Ⅱ卷到第Ⅴ卷所包 含的规则和技术条文，是RCC-M的索引和指南。
▪ 第Ⅰ卷的Z篇汇集了一些技术性附录。强制性附录：用罗 马数字编号，如Z Ⅲ； 非强制性附录：用字母编号,如Z D。
ASME与RCC-M的对应关系
ASME NCA分卷 NB分卷一级设备 附录
表C3383 不同准则级的应力限值
准则级别 O或A级 B级 C级 D级 试验
应力限值
σm≤S (σm或σL)+σb≤1.5S σm≤1.1S (σm或σL) +σb≤1.65S σm≤1.5S (σm或σL) +σb≤1.8S σm≤2S (σm或σL) +σb≤2.4S σm≤0.95Sy (σm或σL) +σb≤1.4Sy
RSS8-2424HP中文资料
Deviation / Load
Deviation from Nominal (%)
15.000 10.000 5.000 0.000 -5.000 -10.000
Deviation from Nominal (%)
3.305
0505
15.000 10.000 5.000 0.000 -5.000 -10.000
Input Voltage Range Output Voltage Accuracy Line Voltage Regulation Load Voltage Regulation (10% to 100% full load) Output Ripple and Noise (20MHz limited) Operating Frequency Efficiency at Full Load No Load Power Consumption Isolation Voltage Rated Working Voltage Isolation Capacitance Isolation Resistance Short Circuit Protection P-Suffix Operating Temperature Range (free air convection) Storage Temperature Range Reflow Temperature ROHS compliant (for more details see Application Notes) Relative Humidity 1.8V, 3.3V output types 5V output type 9V, 12V, 15V, 24V output types ±10% ±5% 1.2%/1% of Vin typ. 20% max. 15% max. 10% max. 100mVp-p max. 50kHz min. / 100kHz typ. / 105kHz max. 70% min. / 80% typ. RSS & RSS8 types 101mW min. / 126mW typ. / 220mW max. RSD & RSD10 types 87mW min. / 130mW typ. / 230mW max. (tested for 1 second) 1000VDC min. H-Suffix (tested for 1 second) 3000VDC min. (long term isolation) see Application Notes 15pF min. / 70pF max. 10 GΩ min. 1 Second Continuous -40°C to +85°C (see Graph) -55°C to +125°C 245°C (30 sec) max. 95% RH continued on next page July-2006
SS18阳性滑膜肉瘤中ER-PR阳性亚型的临床病理研究及ALK-C-met高表达的意义
SS18阳性滑膜肉瘤中ER-PR阳性亚型的临床病理研究及ALK-C-met高表达的意义摘要：目的：本研究旨在探讨SS18阳性滑膜肉瘤中ER/PR阳性亚型的临床病理特征及ALK/C-met高表达的意义，为肿瘤的治疗和预后提供可靠依据。
方法：采用回顾性研究的方法，回顾性分析了2010年至2019年间确诊为SS18阳性滑膜肉瘤的患者的临床资料及病理检查结果，筛选出ER/PR阳性亚型的患者，通过免疫组化检测ALK 和C-met的表达情况，对患者的预后进行分析。
结果：共纳入了60例滑膜肉瘤患者，其中13例（21.7%）表现为ER/PR阳性亚型。
ALK和C-met的高表达率分别为38.5%和61.5%。
ER/PR阳性患者的平均年龄为32岁，男女比例为1:2。
临床表现以关节肿痛和运动障碍为主，病理分化程度为Ⅱ-Ⅲ级。
ALK和C-met高表达与ER/PR阳性患者、年龄、临床表现及分化程度等相关因素无明显关系。
但观察发现，ALK 和C-met的高表达与滑膜肉瘤的预后密切相关。
结论：ER/PR阳性亚型的滑膜肉瘤具有特殊的临床病理特征，ALK和C-met的高表达可作为滑膜肉瘤预后的重要指标，进一步的研究有助于为患者提供更加精准的诊疗方案和治疗策略。
关键词：SS18阳性滑膜肉瘤；ER/PR阳性亚型；ALK；C-met；临床病理特征；预后Clinical and pathological study of ER/PR-positive subtype in SS18-positive synovial sarcoma and its significance of high expression of ALK/C-metAbstract:Objective: The study aimed to investigate the clinical and pathological characteristics of ER/PR-positive subtype in SS18-positive synovial sarcoma and the significance of high expression of ALK/C-met, providing reliable basis for the treatment and prognosis of tumors.Methods: The retrospective study method was used to retrospectively analyze the clinical data and pathological examination results of patients diagnosed with SS18-positive synovial sarcoma from 2010 to 2019. ER/PR-positive subtype of patients was screened out. The expression of ALK and C-met was detected by immunohistochemistry, and the prognosis of patients was analyzed.Results: a total of 60 synovial sarcoma patients wereincluded, 13 of whom (21.7%) showed ER/PR-positive subtype. The high expression rates of ALK and C-met were 38.5% and 61.5%, respectively. The average age of ER/PR-positive patients was 32 years old, and theratio of men to women was 1:2. The clinical manifestations were mainly joint swelling and motion disorders, and the pathological differentiation degree was II-III level. The high expression of ALK and C-met was not significantly related to ER/PR-positive patients, age, clinical manifestations,differentiation degree, and other related factors. However, it was found that the high expression of ALK and C-met was closely related to the prognosis of synovial sarcoma.Conclusion: ER/PR-positive subtype of synovial sarcoma has special clinical and pathological characteristics. High expression of ALK and C-met can be used as an important indicator of the prognosis of synovial sarcoma. Further research can provide more accurate diagnosis and treatment plans and strategies for patients.Keywords: SS18-positive synovial sarcoma; ER/PR-positive subtype; ALK; C-met; clinical andpathological characteristics; prognosiIn recent years, advances in molecular diagnostic methods have revealed the complexity and heterogeneity of synovial sarcoma, paving the way for personalized treatment based on the molecular characteristics of the tumor. The ER/PR-positive subtype, which is more common in females and has lower metastatic potential, has distinct clinical and pathological features, including an earlier age of onset, a smaller tumor size, and a higher rate of lymph node involvement.Recent studies have shown that ALK and C-met play important roles in the pathogenesis and progression of synovial sarcoma. High levels of ALK expression have been associated with a poor prognosis and resistance to chemotherapy, while high levels of C-met expression have been linked to a higher rate of metastasis and decreased overall survival. Therefore, the expression levels of ALK and C-met can serve as important indicators of the prognosis of synovial sarcoma and can guide treatment decisions.Overall, the ER/PR-positive subtype of synovial sarcoma has unique clinical and pathological characteristics that distinguish it from other subtypes of this rare cancer. The identification of molecular markers such as ALK and C-met can provide valuable prognostic information that can guide thedevelopment of individualized treatment plans for patients with synovial sarcoma. Further research is needed to better understand the molecular mechanisms underlying synovial sarcoma and to develop more effective therapies for this challenging diseaseIn addition to ALK and C-met, other molecular markers have been investigated as potential prognostic indicators for synovial sarcoma. For example, the expression of EZH2, a histone methyltransferase, has been found to correlate with poor prognosis in synovial sarcoma patients (Glenisson et al., 2021). Similarly, high levels of the protein CDK6, aregulator of the cell cycle, have been associated with decreased survival in synovial sarcoma patients (Dufresne et al., 2019).The role of immunotherapy in the treatment of synovial sarcoma is also an area of active research.Preclinical studies have shown that synovial sarcoma cells express high levels of PD-L1, a protein that can inhibit immune responses, suggesting that immune checkpoint inhibitors may be effective in treating these tumors (Lee et al., 2019). However, clinical trials investigating the use of immune checkpoint inhibitors in synovial sarcoma have had mixed results, with some patients showing significant responses whileothers do not benefit from the treatment (Toulmonde et al., 2020).In addition to the development of targeted therapies and immunotherapies, efforts are also underway to improve the detection and diagnosis of synovial sarcoma. Advances in imaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), have allowed for more accurate diagnosis and staging of this disease (Brisson-Noël et al., 2018). Furthermore, the use of liquid biopsy techniques, which involve analyzing tumor DNA in the blood, may provide a non-invasive method for monitoring the progression of synovial sarcoma and detecting early signs of recurrence (Eberhardt et al., 2020).In conclusion, synovial sarcoma is a rare and aggressive cancer that poses significant challengesfor clinicians and researchers. Advances in our understanding of the molecular mechanisms underlying this disease have provided new opportunities for the development of targeted therapies and immunotherapies. However, further research is needed to improve the accuracy of diagnosis and develop more effective treatments for this devastating diseaseSynovial sarcoma is a complex disease that requires a multidisciplinary approach to diagnosis and treatment. The rarity and aggressiveness of the disease, coupled with the lack of effective treatments, make it a significant challenge for patients, clinicians, and researchers alike. Despite these challenges, recent advances in understanding the molecular and genetic mechanisms underlying the disease offer new hope for the development of effective treatments.One of the key challenges in diagnosing synovial sarcoma is distinguishing it from other soft tissue sarcomas. Accurate diagnosis is critical for determining appropriate treatment options andpredicting patient outcomes. However, the overlapping clinical and radiological features of synovial sarcoma with other sarcomas can make diagnosis challenging. Molecular diagnostics, including the use of FISH and PCR techniques, can help confirm the diagnosis and distinguish synovial sarcoma from other sarcomas.Treatment options for synovial sarcoma are currently limited, and outcomes for patients are often poor. Surgery remains the primary treatment option, and adjuvant therapies, such as radiation and chemotherapy, may be used to improve outcomes. However, the effectiveness of these treatments is limited, and thetoxicities associated with chemotherapy can be significant.Recent studies have identified new potential targets for the development of targeted therapies and immunotherapies for synovial sarcoma. These studies have identified a variety of potential molecular targets, including the SS18-SSX fusion protein, which is unique to synovial sarcoma and is thought to play a critical role in the development of the disease. Immunotherapies, such as checkpoint inhibitors and CAR T-cell therapies, have also shown promise in preclinical studies, and may offer new treatment options for patients with synovial sarcoma.In conclusion, synovial sarcoma is a challenging and complex disease that requires a multidisciplinary approach to diagnosis and treatment. While current treatment options are limited, advances in our understanding of the molecular and genetic mechanisms underlying the disease offer new opportunities for the development of effective targeted therapies and immunotherapies. Further research is needed to improve the accuracy of diagnosis and develop more effective treatments for this devastating diseaseIn conclusion, synovial sarcoma is a complex and challenging disease that requires a multidisciplinary approach to diagnosis and treatment. While current treatment options are limited, ongoing research into the molecular and genetic mechanisms of the disease offers new opportunities for targeted therapies and immunotherapies. Further research is needed to improve the accuracy of diagnosis and develop more effective treatments for this devastating disease。
RBM-053.3D中文资料
Specifications (Core Operating Area) and Operating Temperature / Derating-Graph
Input Voltage Input Filter Output Accuracy Line Voltage Regulation Load Voltage Regulation (10% to 100% full load) Ripple and Noise (20MHz limited) Efficiency at Full Load Isolation Voltage Isolation Resistance (Viso = 500VDC) Isolation Capacitance Short Circuit Protection Switching Frequency at Full Load Operating Temperature Storage Temperature Package Weight EC 22 August 2002 1.8V, 3.3V output types 5V output type 9V, 12V, 15V, 24V output types ±10% Capacitor type ±5% 1,2%/1% V Input 20% max. 15% max. 10% max.
元器件交易网
ECONOLINE - DC/DC-Converter
RBM Series, 1 Watt, SIP6 Micro Size Package (Single & Dual Output) Package Style and Pinning (mm)
7.70
0.51 typ.
4.10
s1000总述rccm中文版法国民用核电标准.doc
S1000总述S1100概述S1110预先验证，评定和验收在采用某种焊接工艺时.首先应进行下述验证、评定和验收试验：——材料焊接性能的预先验证（见S1200）——焊接填充材料的批量验收试验（见S2000）——焊接工艺评定（见S3000）——针对采用某种焊接工艺的焊工和焊接操作工的考核（见S4000）——根据S5000对焊接填充材料的评定（见S5000）——焊接车间的评定（见S6000）在本卷各章中规定的各种评定之间的主要关系概述如下：——只有根据S5000的规定，建立焊接填充材料工艺评定数据卡片后，才能对焊接填充材料进行批量验收。
该工艺评定数据卡片规定了材料的批量范围及其使用条件。
——应根据S3143的规定，对焊接工艺评定时所使用的焊接填充材料的任何批量进行验收。
——已经通过焊接工艺的评定试验的焊工或焊接操作工有资格在S4000章规定的范围内使用该种工艺。
其它焊工或焊接操作工如果通过符合S4000规定的考核试验，则可以使用该种焊接工艺。
——焊接工艺评定可免去使用过的焊接填充材料在S5131.3规定的标准试件上的试验。
工艺评定报告可用来代替S5143规定的焊接工艺评定记录。
如果涉及焊接填充材料评定有效范围的有关章节（S3215、S3315、S3415、S3615、S3815）的条件得到满足时，焊接填充材料的牌号或制造条件的改变不会影响焊接工艺的评定。
否则必须按S5000的规定重新进行焊接填充材料的评定。
——焊接工艺评定应在使用过这个工艺的车间内进行，但在满足S6000规定的条件下，允许从一个车间转移到另一个车间或现场。
——S5000规定的焊接填充材料评定后要求的标准试件的试验应在根据S6000评定过的制造车间内进行，所用的焊接填充材料应按S2000的规定验收。
注：在碳钢低合金钢或合金钢表面上熔敷耐磨层，在S8000章中作为专题讨论。
S1120焊接数据包每个焊接数据包对应一个设备。
承压设备和堆内构件都要求有焊接数据包，其内容包括：——标记出全部焊接接头位置的设备总图或简图。
RSM06DRMD-S664中文资料
* Accommodates .093" or .125" mating PCB (Consult factory for .032" boards) * PBT or PPS insulator * Molded-in key available * 3 amp current rating * 10 milli ohm maximum at rated current DUAL (D) HALF LOADED (H)
RIGHT ANGLE (TA,TB,TM)
STRAIGHT PIN (RS, RM) TERMINATIONS
LOOP BELLOWS (RS,RM)
RIGHT ANGLE DIP SOLDER (TA,TB,TM)
.125 [3.18] #4-40
D = .250 [6.35] T = .250 [6.35]
MILLIMETERS C D + 0.38 + 0.25 _ _ 31.01 38.94 46.86 54.79 66.68 78.56 86.49 94.41 102.34 106.30 118.19 126.11 130.07 149.89 165.74 177.62 38.96 46.89 54.81 62.74 74.63 86.51 94.44 102.36 110.29 114.25 126.14 134.06 138.02 157.84 173.69 185.57
E + .020 _ 1.784 2.096 2.408 2.720 3.188 3.656 3.968 4.280 4.592 4.748 5.216 5.528 5.684 6.464 7.088 7.556
ss00中文资料
CE
益-带宽 I =50mA
乘积
C
h 分级 FE 分级 h FE2
典型特性
B 85—160
0.66 9
100
190
C 120—200
1
V
pFMHzD 160— Nhomakorabea00图 1 静态特性曲线
图 2 直流电流增益
图 3 基极-发射极饱和电压 集电极-发射极饱和电压
图 4 基极-发射极导通电压 图 5 集电极输出电容
CBO
C
基极击穿 A，I =0
电压
E
BV
集电极- I =2mA， 25
CEO
C
发射极击 I =0
穿电压
B
BV
发射极- I =100μ 6
EBO
E
基极击穿 A，I =0
电压
C
I
集电极关 V =35V，
CBO
CB
断电流 I =0
E
I
发射极关 V =6V，
EBO
EB
断电流 I =0
C
h
直流电流 V =1V， 45
135 160 110 0.28 0.98
最大值
100 100 300 300 300 0.5 1.2
单位 V V V nA nA
V V
续表
V (on) BE C ob f T
基极-发 V =1V，
CE
射极导通 I =10mA
电压
C
输出电容 VCB=10V ，I =0，
E
f=1MHz
电流增 V =10V，
SS8050 便携式收音机用 2 瓦 B 类推挽输出放大器
与 SS8550 配对使用
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
RCM-SS CS-2469 10/25/04Page 1 of 2Features•Six addressable Form-C relaycontacts.
•Removable 12 AWG (3.25 mm²)to 18 AWG (0.9 mm²) plug-interminal blocks.
•Status indicators for each point.•Unused addresses may bedisabled.
•Rotary address switches.•Compatible with Gamewell’s602, 610, 632, 654 and 658FACPs with SmartScan™ SLC.
•Mount one or two modules in aBB-XP cabinet (optional).
•Mount up to six modules on aCHS-6 chassis in a BB-25cabinet (optional).
•Mounting hardware included.
ListingsListings and approvals belowapply to the RCM-SS Six-RelayAddressable Control Module. Insome cases, the module maynot be listed by certain approvalagencies, or listing may be inprocess. Consult factory forlatest listing status.
•UL Listed: file S521.•CSFM approved:file 7300-1288:169.
•MEA approved:file 368-01-E Vol. II.
DescriptionGamewell’s SmartScanTM RCM-SSsix-relay control module providesan intelligent alarm system with sixForm-C relays.
The first module is addressed from01 to 94 while the remaining mod-ules are automatically assigned tothe next five higher addresses. Pro-visions are included for disabling amaximum of three unused modules.A single isolated set of dry relaycontacts is provided for each mod-ule address, which is capable ofbeing wired for either a normally-open or normally-closed operation.The module allows the control panelto switch these contacts on com-mand. No supervision is provided forthe controlled circuit.
Each RCM-SS module has panel-controlled green LED indicators. The panel can cause the LEDs to blink, latchon, or latch off.
Product Line InformationRCM-SS: Six-relay control module.BB-XP: Optional cabinet for one or two modules. Dimensions, DOOR: 9.234"(23.454 cm) wide (9.484" [24.089 cm] including hinges), x 12.218" (31.0337 cm)high, x 0.672" (1.7068 cm) deep; BACKBOX: 9.0" (22.860 cm) wide (9.25"[23.495 cm] including hinges), x 12.0" (30.480 cm) high x 2.75" (6.985 cm); CHAS-SIS (installed): 7.150" (18.161 cm) wide overall x 7.312" (18.5725 cm) high inte-rior overall x 2.156" (5.4762 cm) deep overall.
BB-25: Optional cabinet for up to six modules mounted on CHS-6 chassis (be-low). Dimensions, DOOR: 24.0" (60.96 cm) wide x 12.632" (32.0852 cm) high, x1.25" (3.175 cm) deep, hinged at bottom; BACKBOX: 24.0" (60.96 cm) wide x12.550" (31.877 cm) high x 5.218" (13.2537 cm) deep.
CHS-6: Chassis, mounts up to six modules in a BB-25 cabinet.
RCM-SSSix-Relay Addressable Control Module
元器件交易网www.cecb2b.comRCM-SS CS-2469 10/25/04Page 2 of 2Gamewell12 Clintonville RoadNorthford, CT 06472-1610Phone: 203-484-7161Fax: 203-484-7118www.gamewell.com
A Honeywell Company© 2004 Gamewell
Specifications and wiring information are provided for information only and are believedto be accurate. Gamewell assumes no responsibility for their use.Data and design are subject to change without notice. Installation and wiringinstructions shipped with the product shall always be used for actual installation. Formore information, contact Gamewell.
Wiring DiagramStandby current1.45 mA (SLC current draw with all ad-dresses used; if some addresses aredisabled, the standby current de-creases).Alarm current32 mA (assumes all six relays have beenswitched once and all six LEDs solidON).Temperature range32°F to 120°F (0°C to 49°C).Humidity10% to 85% noncondensing.SpecificationsDimensions6.8" (172.72 mm) high x 5.8" (147.32mm) wide x 1.0" (25.40 mm) deep.
Shipping weight1.1 lb. (0.499 kg) including packaging.Mounting optionsCHS-6 chassis, BB-25 cabinet.Relay current30 mA/relay pulse (15.6 ms pulse dura-tion), pulse under panel control.
Relay contact ratings30 VDC; 70.7 VAC.
Current ratings•3.0 A @ 30 VDC maximum, resistive,non-coded.•2.0 A @ 30 VDC maximum, resistive,coded.•1.0 A @ 30 VDC maximum, inductive(L/R = 2 ms), coded.•0.5 A @ 30 VDC maximum, inductive(L/R = 5 ms), coded.•0.9 A @ 110 VDC maximum, resistive,non-coded.•0.9 A @ 125 VAC maximum, resistive,non-coded.•0.7 A @ 70.7 VAC maximum, inductive(PF = 0.35), non-coded.•0.5 A @ 125 VAC maximum, inductive (PF= 0.35), non-coded.
6926wir1.wmf
元器件交易网www.cecb2b.com